Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide with Ascorbic Acid in Relapsed/Refractory Multiple Myeloma
NCT00006021Phase 2Completed
- Sponsor
- University of Miami
- Start
- Jun 2000
- Primary completion
- May 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in multiple myeloma (MM), sponsored by University of Miami. Primary endpoint: Disease response as measured by M protein quantitation and plasma cell infiltration. Started Jun 2000; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00006021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006021.